CEP162

Across TCGA pan-cancer cohorts, CEP162 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP162 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CEP162 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP162 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

STAD, UCEC, and SKCM are the cancer types where CEP162 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.128	0.679	<.001	36	view →
UCEC	DFS	Median	All	0.973	0.614	.003	36	view →
SKCM	DFS	Median	III,IV	0.242	0.513	.021	9	view →
BLCA	DFS	Median	All	1.000	0.330	.033	6	view →
LUAD	OS	Median	All	0.394	0.676	.020	4	view →
COAD	DFS	Median	All	0.536	0.786	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP162–STAD (OS)

Open the STAD breakdown →